Arena Pharma (ARNA) Tops Q2 EPS by 3c

Arena Pharma (NASDAQ: ARNA) reported Q2 EPS of ($0.11), $0.03 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $9.18 million versus the consensus estimate of $10.95 million.

Arena Research & Development

• Announced the initiation of patient screening in a Phase 2 proof-of-concept clinical trial of APD334, an oral Sphingosine 1-Phosphate Subtype 1 (S1P1) receptor modulator for autoimmune diseases, being studied in this trial for the treatment of ulcerative colitis.
• Arena and Roivant Sciences Ltd. entered into a Development, Marketing and Supply Agreement for nelotanserin, Arena's internally discovered inverse agonist of the serotonin 2A receptor.
• Announced results from a Phase 1 single-ascending dose clinical trial of APD371, a highly selective and potent cannabinoid 2 (CB2) receptor agonist in development as a potential treatment for pain.

BELVIQ® (lorcaserin HCl) Update

• IMS Health estimates that approximately 183,000 prescriptions for BELVIQ were filled in the United States in the second quarter of 2015, representing growth in total prescriptions of approximately 66% compared to the same quarter of last year and 8.6% compared to the previous quarter.
• Ildong Pharmaceutical Co., Ltd., estimates that approximately 1.8 million tablets of BELVIQ were prescribed in South Korea in the second quarter of 2015, which equates to approximately 29,000 one-month prescriptions.
• BELVIQ was nominated by the Galien Foundation and Awards Committee for the 2015 Prix Galien USA Award in the Best Pharmaceutical Agent category.
• Arena and Eisai presented posters on lorcaserin HCl research findings at the American Diabetes Association's 75th Scientific Sessions, American Thoracic Society International Conference and at the International Society for Pharmacoeconomics and Outcomes Research.

For earnings history and earnings-related data on Arena Pharma (ARNA) click here.

You May Also Be Interested In

• Lockheed Martin (LMT) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY24 Guidance
• NextEra Energy (NEE) Tops Q1 EPS by 16c, provides guidance
• Kiniksa Pharmaceuticals, Ltd. (KNSA) Misses Q1 EPS by 11c; raises guidance